Medical Advocates
Abacavir/Lamivudine/Zidovudine (Trizivir)
 
Journal Papers, Abstracts, and
Commentaries

General Reports
 Resistance
 Adverse Events
 Efficacy
 Therapeutic Strategies
 Discontinuation

 


 
rizivir Main Page Main New/Newsworthy  Home Page      
Last Updated:  August 13, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 

Trizivir.
 Keiser P, Nassar N.
 Expert Opin Pharmacother 2002 May;3(5):619-24        
Abstract
Resistance
 
 
Modulation of K65R Selection by Zidovudine Inclusion: Analysis of HIV Resistance Selection
in Subjects with Virologic Failure Receiving Once-Daily Abacavir/Lamivudine/Zidovudine and
Tenofovir DF (Study COL40263).
 Ross L, Elion R, Lanier R, , et al 
AIDS Res Hum Retroviruses. 2009 Jun 29

Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and
zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Ait-Khaled M, Rakik A, Griffin P, et al.
Antivir Ther 2002 Mar;7(1):43-51
 Abstract
Adverse Events
 
 
Inflammatory Biomarker Changes and their Correlation with Framingham Cardiovascular Risk and Lipid Changes in ARV Therapy in ARV-Naive HIV=Infected Petitions Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without  ritonavir in ARIES.
 Young B, Squires K, Ross LL, et al
AIDS Res Hum Retroviruses. 2012 Oct 8.
 Abstract

Hypersensitive reaction to abacavir or syphilitic hepatitis?
 Dumouchel-Champagne H, Bouhour D, Ferry T, et al
Presse Med. 2003 Oct 11;32(33):1557-8
 Abstract

Recurrent hypersensitivity to Combivir.
Winston A, McLean K.
Int J STD AIDS. 2002 Mar;13(3):213-4.
 Abstract
Viral Dynamics
 
   
Efficacy
 
 
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
 Cruciani M, Mengoli C, Serpelloni G, et al
Cochrane Database Syst Rev. 2013 Jun 5;6:
 Abstract

Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS, Kongnyuy EJ, Alobwede SM, Wiysonge CS.
 Cochrane Database Syst Rev. 2013 Mar 28;3:CD005481
 Abstract

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1
Coinfected Adults: 48-Week Data.
Rodriguez AE, Dejesus E, Williams V,  et al
Open AIDS J. 2010 Oct 21;4:167-70.
 Abstract

Abacavir/Lamivudine/Zidovudine Maintenance After Standard Induction in
Antiretroviral Therapy-Naīve Patients: FREE Randomized Trial Interim Results.
 Sprenger HG, Langebeek N, Mulder PG, et al
AIDS Patient Care STDS. 2010 Jun 1.
 Abstract

Low-abundance HIV species and their impact on mutational profiles in patients
with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
 Ross LL, Rouse E, Gerondelis P,et al  
J Antimicrob Chemother 2010 Feb;65(2):307-15.
 Abstract

A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating
HIV infection and AIDS.
Shey M, Kongnyuy EJ, Shang J, Wiysonge CS.
Cochrane Database Syst Rev. 2009 Jul 8;(3):CD005481.
 Abstract

FULL-TEXT PDF ARTICLE
A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine
twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected
patients over 48 weeks (ESS100327, the ACTION Study).
 Kumar PN, Salvato P, Lamarca A, et al 
AIDS Res Ther. 2009 Apr 9;6(1):3.
Paper

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone
in naive HIV-1-infected adults.
 Mallolas J, Pich J, Peņaranda M, et al
AIDS. 2008 Jan 30;22(3):377-84.
 Abstract
 
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and
zidovudine: the Swiss HIV Cohort Study.
 Wolbers M, Opravil M, von Wyl V, et al
AIDS. 2007 Oct;21(16):2201-2207.
 Abstract
 

Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained
HIV Load Suppression: Four Years of Follow-up.
d'Ettorre G, Zaffiri L, Ceccarelli Gm et al
HIV Clin Trials. 2007 May-Jun;8(3):182-8.
 Abstract
 
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/
nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex
and ethnicity.
 Kumar P, Rodriguez-French A, Thompson M,  et al
 HIV Med. 2006 Mar;7(2):85-98.
Abstract
 
Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive
HIV-Infected Patients: Results From a Large Multicenter Observational Cohort.
 Berenguer J, Perez-Elias MJ, Bellon JM 
J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):154-159.
 Abstract
 
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Orkin C, Stebbing J, Nelson M,  et al  
 J Antimicrob Chemother. 2005 Feb;55(2):246-51
 Abstract
 
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of
HIV-1 infection.
 Gulick RM, Ribaudo HJ, Shikuma CM  
N Engl J Med. 2004 Apr 29;350(18):1850-61.
Abstract
 
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with
human immunodeficiency virus-1 infection: a formulation-switch trial.
 Fischl MA, Burnside AE Jr, Farthing CE, et al
 Pharmacotherapy. 2003 Nov;23(11):1432-40
 Abstract
 
Impact of an Educational Program on Efficacy and Adherence With a Twice-Daily
Lamivudine/Zidovudine/Abacavir Regimen in Underrepresented HIV-Infected Patients.
Rawlings MK, Thompson MA, Farthing CF, et al 
J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.
 Abstract
 
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to
combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
 John M, McKinnon EJ, James IR   
J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33.
 Abstract

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine
combination tablet): 48 weeks efficacy,safety and adherence results.
Katlama C, Fenske S, Gazzard B,  et al  
HIV Med 2003 Apr;4(2):79-86
 Abstract

Comparison of Metabolic Abnormalities and Clinical Lipodystrophy 48 Weeks After Switching
from HAART to Trizivir Versus Continued HAART: The Trizal Study.
 Lafeuillade A, Clumeck N, Mallolas J,
HIV Clin Trials 2003 Jan-Feb;4(1):37-43
 Abstract

A randomized trial of simplified maintenance therapy with abacavir,lamivudine, and zidovudine
in human immunodeficiency virus infection.
Opravil M, Hirschel B, Lazzarin A, et al.
 Infect Dis 2002 May 1;185(9):1251-60
 Abstract

A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine i
n HIV-infected naive patients (the Combine Study).
Podzamczer D, Ferrer E, Consiglio E, et al
Antivir Ther. 2002 Jun;7(2):81-90
 Abstract
 
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated
patients with HIV infection taking directly observed treatment.
Kirkland LR, Fischl MA, Tashima KT, et al
Clin Infect Dis 2002 Feb 15;34(4):511-8
 Abstract

Simplification with abacavir-based triple nucleoside therapy versus continued protease
inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable
plasma HIV-1 RNA.
Clumeck N, Goebel F, Rozenbaum W, et al
AIDS 2001 Aug 17;15(12):1517-26
 Abstract

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive
HIV-infected adults: A randomized equivalence trial.
Staszewski S, Keiser P, Montaner J, et al
 JAMA 2001 Mar 7;285(9):1155-63
 Abstract

AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine
plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-
naive patients.
AIDS 2000 Mar 10;14(4):367-74
 Abstract
Therapeutic Strategies
 
HIV/TB Coinfection
 
  Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV
and tuberculosis in Uganda.
 Srikantiah P, Walusimbi MN, Kayanja HK, et al;  
 AIDS. 2007 Sep;21(14):1972-1974.
Abstract
 
Salvage Therapy
 
  Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with
suppression of viraemia and a decreased cholesterol.
 Latham V, Stebbing J, Mandalia S, et al 
J Antimicrob Chemother. 2005 May 23;
 Abstract
Discontinuation of Therapy
 
  An analysis pf causes for the discontinuation of a simplified antiretroviral regimen with abacavir,
lamivudine and zidovudine.
 Morillo Verdugo R, Abdel-Kader Martin L 
 Farm Hosp. 2005 Jul;29(3):164-70.
Abstract

Trizivir Main Page Main New/Newsworthy  Home Page      

Trizivir Journal Citations